Will BIIB Bounce After Today's Disaster?

Insiders' Blog Commentary : Biogen Idec (Nasdaq: BIIB) is looking like a possible dead-cat bounce play after today's 45% sell-off on the Tysabri fallout. The stock is currently at $36.57/share. We view the litigation risk as minimal. Stock should be worth in low-$40s without the drug.

You May Also Be Interested In

• RBC sees a buying opportunity in this software stock after massive selloff
• Earnings setup for this transportation stock is very positive: DB
• Analyst lists OTA winners and losers of Google's proposed changes to EU search